Otele and Kovacevic for a combined £9 million is an absolute steal. If we have any aspirations of winning the title, then Michael Nicholson needs to go all out to snap them up… As touched on by my ...

On Sunday, Nick Kyrgios enjoyed a winning return to the Brisbane International by partnering good friend Thansai Kokkinakis to a doubles victory over Matthew Ebden and Rajeev Ram. Two days later, he ...

A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose ...

New Jersey returns home following a four-game road trip to host the Seattle Kraken at Prudential Center. Puck drop is 7 p.m. ET. Read below for your game preview presented by Training Innovations and ...

Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Shortly after scoring a historic FDA nod for its Wegovy pill, Novo Nordisk is off to the races with the oral obesity med’s launch. The once-daily pill officially debuted in the U.S. Monday, with the ...

Novo Nordisk’s NOVO.B1.17%increase; green up pointing triangle Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish ...

Novo Nordisk’s (NYSE: NVO) Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x story moving forward, provided it effectively ...

American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices for the drug, called the Wegovy ...

The Wegovy pill is the first and only oral GLP-1 for weight loss in adults. The first and only oral GLP-1 for weight loss in adults is now available to consumers. Drugmaker Novo Nordisk announced ...

Novo launches Wegovy pill in competitive obesity drug market Eli Lilly expects weight-loss pill decision later this year Novo targets self-pay market with oral option over injectable Starter dose of ...

Its newly earned indications could impact financial results in 2026. The drugmaker should also make decent pipeline progress. Novo Nordisk's shares look reasonably valued. Thankfully, 2026 could be a ...